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Abstract Substrates for the Organic Cation Transporter 1,
encoded by the SLC22A1 gene, are metformin, amantadine,
pramipexole, and, possibly, levodopa. Recently, we identi-
fied that the rs622342 A > C polymorphism is associated
with the HbA1c lowering effect in metformin users. In the
Rotterdam Study, we associated this polymorphism with
higher prescribed doses of all anti-Parkinsonian drugs.
Between the first and fifth prescriptions for levodopa, for
each minor rs622342 C allele, the prescribed doses were
0.34 defined daily dose higher (95% CI 0.064, 0.62; p=
0.017). The mortality ratio after start of levodopa therapy
was 1.47 times higher (95% CI 1.01, 2.13; p=0.045).
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Introduction
Transporter proteins have a major role in the absorption,
distribution, and elimination of a wide variety of com-
pounds. Organic cation transporters (OCT) are involved in
the carriage of both endogenous compounds, such as
dopamine, and drugs, such as metformin and some anti-
Parkinsonian drugs [1–3]. The three most important
members of the OCT family are OCT1, OCT2, and
OCT3, encoded by the SLC22A1, SLC22A2, and SLC22A3
genes, respectively. Pramipexole and amantadine are sub-
strates for OCT1 and OCT2 [2, 4–6]. Levodopa is a
substrate for OCT, although the subtype has not yet been
identified [7, 8].
Recently, we identified that the polymorphism rs622342
A > C in the SLC22A1 gene, coding for OCT1, was
associated with the reduction in HbA1c levels in incident
metformin users [9]. As this polymorphism might also be
involved in the transportation efficacy of anti-Parkinsonian
drugs, it may affect the response to these drugs. In this
population-based cohort study, we studied whether pre-
scribed doses of levodopa and co-prescribed anti-
Parkinsonian drugs differed between rs622342 genotypes
in incident levodopa users. We also studied the difference in
survival time after start of levodopa therapy.
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Methods
Data for these analyses were obtained from the Rotterdam
Study, a prospective population-based cohort study of 7,983
Caucasians aged 55 years and older, who were followed
from 1990 onwards [10]. All participants of the Rotterdam
Study gave written informed consent. Ethical approval was
obtained from the Medical Ethical Committee of the
Erasmus MC.
The study sample consisted of all subjects in the
Rotterdam Study who had a first prescription for levodopa
between July 1st 1991 and January 1st 2008. Participants
who had prescriptions for levodopa between January 1st
1991 and July 1st 1991 were excluded to ensure that only
incident levodopa users were included. We also excluded
all participants who were prescribed less than three
prescriptions for levodopa, because, most likely, levodopa
treatment was used as a diagnostic tool. Participants were
genotyped with the Illumina 550k SNP array [11].
Patients were followed from the first prescription of
levodopa onwards, irrespective of whether they used other
anti-Parkinsonian drugs at or before the date of the first
levodopa prescription. We used two types of study outcome.
First, for every prescription of levodopa, the change in
prescribed daily dose of levodopa plus the dose of co-
prescribed other anti-Parkinsonian drugs (anticholinergic
drugs, amantadine, bromocriptine, pergolide, ropinirole,
pramipexole, selegiline, and entacapone) compared to the
prescribed daily doses at the time of the first levodopa was
calculated. To make the prescribed doses of different anti-
Parkinsonian drugs comparable to each other, we divided
the prescribed daily dose by the defined daily dose (DDD).
The DDD is a standardized dosing measure representing the
recommended daily dose for the main indication in an adult.
The defined daily doses of controlled release levodopa
prescriptions were multiplied by 0.7 to correct for differ-
ences in bioavailability. Associations between the number of
rs622342 variant C alleles and changes in cumulative
prescribed doses were analyzed using multivariate linear
regression. We separately analyzed the associations between
genotype and start of dopamine agonist therapy and time to
discontinuation of levodopa therapy with Cox proportional
hazard models. Second, we analyzed the difference between
rs622342 genotypes in time from the first prescription for
levodopa until death due to any cause with Cox proportional
hazard models. Analyses were adjusted for age and sex.
Results
In the Rotterdam Study, 99 participants were identified who
were incident levodopa users (Table 1). The minor allele
frequency of rs622342 (C allele) was 0.36, and the
genotype distribution was in Hardy–Weinberg equilibrium
(p=0.45). No statistically significant differences were found
in time until the first prescription for levodopa in the whole
Rotterdam Study, the prescribed doses at start of levodopa
therapy, or use of other anti-Parkinsonian drugs at start of
levodopa therapy. The average time that drugs were
dispensed for per levodopa prescription was 52.5 days,
and the rs622342 genotype was not associated with this
duration.
The average prescribed dose of levodopa and co-
prescribed drugs increased after start of levodopa therapy.
The increase was higher with the number of variant C alleles
(Fig. 1). With each minor C allele, the change in prescribed
daily dose of all anti-Parkinsonian drugs between the first
and fifth prescriptions for levodopa was 0.34 DDD higher
(95% CI 0.064, 0.62). The prescribed daily dose of
levodopa was 0.01 DDD higher (95% CI −0.035, 0.062)
Table 1 Baseline characteristics
rs622342 AA AC CC
N 39 49 11
Gender, male (%) 17 (43%) 22 (45%) 3 (27%)
Age, year (SD) 77.7 (7.1) 78.0 (7.4) 78.8 (7.5)
Follow-up, year (SD) In Rotterdam Study 11.8 (4.5) 10.0 (4.1) 9.4 (5.0)
After start levodopa 5.0 (3.8) 4.6 (3.6) 3.5 (2.6)
Body-mass index, kg/m2 (SD) a 28.2 (6.3) 26.2 (3.9) 27.6 (4.8)
Creatinine level, μmol/l (SD) a 85.9 (16.5) 79.9 (14.2) 79.8 (9.7)
Prior use before start levodopa therapy Anticholinergic drugs 5 (13%) 7 (14%) 1 (9%)
Dopamine agonists 3 (8%) 4 (8%) 1 (9%)
Amantadine 12 (31%) 11 (22%) 5 (45%)
Selegiline 13 (33%) 15 (31%) 4 (36%)
Average prescribed dose of non-levodopa anti-Parkinsonian drugs at start levodopa therapy 0.84 DDD 0.80 DDD 0.68 DDD
aAt the time of entrance in the Rotterdam Study
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and the prescribed daily dose of other anti-Parkinsonian
drugs was 0.33 DDD higher (95% CI 0.049, 0.61). The
change in prescribed daily dose was 0.038 DDD (95%
CI −0.007, 0.083) for the anticholinergic drugs, 0.11 DDD
(95% CI 0.01, 0.20) for amantadine and 0.19 DDD (95%
CI -0.07, 0.45) for selegiline. Only six patients were
prescribed dopamine agonists at the fifth prescription and
in none of these patients the prescribed daily dose had
changed between the first and fifth levodopa prescription.
Therefore, changes in dopamine agonist doses did not
contribute to the change in total prescribed daily dose of
anti-Parkinson drugs. No significant associations were
found between the rs622342 genotype and start of
dopamine agonist therapy (HR 0.99 95% CI 0.45, 2.19)
or discontinuation of levodopa therapy (HR 1.13 95%
CI 0.72, 1.76).
The average survival time after start of levodopa therapy
differed between rs622342 genotypes. The average survival
time was 6.9 years for patients with the AA genotype,
5.2 years for patients with the AC genotype, and 4.4 years
for patients with the CC genotype. The mortality ratio was
significantly raised with the number of minor C alleles (HR
1.47; 95% CI 1.01, 2.13).
Discussion
In this population-based cohort study, the minor C allele at
rs622342 in the SLC22A1 gene, encoding the transporter
OCT1, was associated with higher prescribed doses of anti-
Parkinsonian drugs and a shorter survival after start of
levodopa therapy. This polymorphism was previously
associated with metformin response and the rs622342
minor C allele is most likely associated with a less
functioning OCT1 transporter. We could not exactly identify
which drug or drugs contributed to the difference in prescribed
daily dose of anti-Parkinsonian drugs. The only individual
drug for which the prescribed daily doses were significantly
associated with the rs622342 genotype was amantadine. We
cannot exclude that the rs622342 variant C allele is associated
with a lower response to levodopa therapy and that this effect
is compensated with higher prescribed doses of amantadine,
selegiline, and possibly other anti-Parkinsonian drugs. The
shorter survival period associated with the C allele of
rs622342 suggests that multiple anti-Parkinsonian drugs are
involved and that the lower response to one or more anti-
Parkinsonian drugs is not compensated by higher prescribed
doses of other drugs.
More transporters than OCT1 are involved in the transpor-
tation of anti-Parkinsonian drugs, such as OCT2 and OCT3
and the L-type amino acid transporter1 and 2. These trans-
porters differ in their expression throughout the body,
distinguishing different roles in absorption, distribution, and
elimination of levodopa. OCT1 is expressed in the liver, small
intestine, and, in small amounts, in the brain [1]. We do not
know the location of transporters that are responsible for the
observed difference and why an effect on OCT1 transporter
capacity is not compensated for by other transporters. It is
possible that the rs622342 C allele results in a reduced anti-
Parkinson drug uptake from the small intestine resulting in a
decreased biological availability [12]. However, OCT1 is
also located in small amounts in the brains, and we cannot
exclude that these transporters are for example the rate-
limiting step for uptake of anti-Parkinson drugs in the brain
and responsible for the difference in anti-Parkinson drug
response between rs622342 genotypes [1].
The rs622342 polymorphism is located in an intron region,
not coding for an amino-acid change. Most likely, this
polymorphism is in linkage disequilibrium with a functional
polymorphism, although we cannot exclude that it has a direct
effect, for example, by affecting gene expression.
In population-based studies, bias may affect the obtained
results. We believe that bias in our study is minimal. We
identified all incident levodopa users in the Rotterdam
Study, and information was collected prospectively, without
prior knowledge of the study hypothesis, making selection
and information bias unlikely. We did not find any
difference in time to levodopa therapy, prior use of other
anti-Parkinson medication, or prescribed doses of anti-
Parkinson drugs at start of levodopa therapy, making it
unlikely that the rs622342 polymorphism affects the
progression to Parkinson’s disease. We did not have
information on the indication of levodopa use; therefore,
we cannot stratify on these indications.
Nine participants were prescribed dopamine agonists and
did not receive prescriptions for levodopa during follow-up.
These participants were not included in this study, because
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Fig. 1 Rs622342 genotype and change in prescribed doses of anti-
Parkinsonian drugs (bars represent standard error)
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we cannot exclude that the dopamine agonists were
prescribed for other indications.
The number of participants in this study was limited;
therefore, we cannot exclude that our results were a false-
positive finding, and replication of these results in another
cohort is indicated.
To conclude, in this population-based cohort study, the
rs622342 minor C variant allele in the SLC22A1 gene,
encoding OCT1, was associated with higher prescribed
doses of anti-Parkinsonian drugs and shorter survival time
after start of levodopa therapy. A possible explanation is that
this variant allele is associated with a decreased efficacy of
the transportation of anti-Parkinsonian drugs by OCT1 to the
brain. The results suggest that patients with the AC or CC
genotype have less response to these drugs and more severe
symptoms, resulting in a shorter survival period.
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